NCT04418401 2026-02-17
CISLD-8
Zhejiang University
Phase 1 Completed
Clinical Trials
4 trialsNCT04402723 2022-12-01
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Terminated
NCT04472858 2022-11-29
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Unknown
NCT04059874 2019-08-16
Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate
First Affiliated Hospital of Zhejiang University
Phase 1 Unknown